Blood culture contamination rate triples in one quarter
A 320-bed community hospital draws about 4,000 blood culture sets per year. The laboratory's quarterly quality report shows the contamination rate - coagulase-negative staphylococci, viridans-group streptococci, diphtheroids, or Bacillus species in one of two or more sets, with no repeat positive - rising from 1.6% to 4.8% over three months. The emergency department draws 62% of sets. Two traveler phlebotomists joined four months ago, and the hospital switched from 2% chlorhexidine/70% isopropyl alcohol to an iodophor wipe during a supply shortage. Several sets were drawn from existing peripheral IV lines during the same period. The antimicrobial stewardship pharmacist reports a parallel rise in vancomycin starts from the ED.
1. How would you investigate this, and what specific data would you collect before changing anything?
Read the worked answer
Treat it as a process problem, not a people problem, and stratify before acting.
Define the measure precisely: contamination = an organism that is normal skin flora grown from one bottle of a set (or one of several sets) in a patient without a plausible source. Report as a rate with a numerator and denominator (contaminated sets ÷ total sets), by month.
Stratify:
- By collector (individual phlebotomist or nurse, and by role).
- By draw site: peripheral venipuncture vs. existing IV line vs. central catheter.
- By location (ED vs. inpatient units) and by shift.
- By time: plot monthly with a statistical process control chart to distinguish a real shift from common-cause variation.
- By organism and time to positivity: a single phlebotomist with clustered Bacillus or diphtheroids suggests technique; multiple organisms in one bottle suggests environmental contamination of the prep supplies.
Direct observation of 15–20 draws: hand hygiene, skin antisepsis agent and full 30-second dry time, whether the bottle tops are disinfected, whether the site is repalpated after prep, and the volume inoculated (adults need roughly 20–30 mL per set; low volume both lowers yield and raises the relative impact of any contaminant).
Confirm the supply change actually occurred as described; iodophor requires a longer dry time than chlorhexidine/alcohol and is a well-described driver of exactly this pattern.
2. Propose a corrective action plan with measurable endpoints, and explain how you would address the one phlebotomist whose rate is far above peers.
Read the worked answer
Interventions, in order of expected yield:
- Restore chlorhexidine/alcohol as the default skin antiseptic with an enforced dry time; document the substitution and its resolution on the quality record.
- Stop drawing routine cultures from existing IV lines; require peripheral venipuncture unless a line draw is specifically authorized.
- Retrain all ED collectors with return demonstration, focusing on prep technique and inoculated volume.
- Two-set standard per episode, drawn from separate sites, with a note on the order that repeat positives are not counted as contamination.
- Feedback loop: post unit-level contamination rates monthly; the ED should own its own number.
Endpoints: contamination rate below 3% within two quarters, sustained for three consecutive months on a control chart; vancomycin starts from the ED returning toward baseline; no increase in true-positive yield.
Handling the outlier collector: verify the denominator is adequate (a phlebotomist with 20 draws can look extreme by chance), then review the data privately with the individual, observe a live draw, and retrain. The goal is correction of technique, not discipline; punitive framing drives under-reporting and hides the problem. Escalate to the supervisor only if retraining does not change the rate, and document each step.
3. What documentation and regulatory obligations attach to this episode?
Read the worked answer
This is a quality indicator failure that requires a documented investigation, regardless of accreditation body:
- Record the indicator definition, the data, the root-cause analysis, the corrective actions, the responsible persons, and the re-measurement plan in the laboratory's quality management record.
- Verify the change: if the antiseptic product changed, confirm the new product was validated for the intended use and that staff competency was reassessed; any new lot or reagent must have documented acceptance testing.
- Competency assessment records for all staff performing blood cultures must reflect the retraining.
- If a new blood culture instrument or method was introduced around the same time, confirm the verification study (accuracy, time to detection, contamination comparison) was completed and approved before patient testing - method verification performed after go-live is a citation.
- Ensure the change was reviewed through the laboratory's quality or infection prevention committee, with minutes, and that results were reported to the medical staff and stewardship program.
- Retention: keep the raw data and the analysis for the period required by the accrediting organization's record-retention policy.
The core principle: an unfavorable trend that is measured, investigated, corrected, and re-measured is a sign of a functioning quality system. The same trend discovered by an inspector is a deficiency.